Last reviewed · How we verify
primary central nervous system lymphoma
Approved treatments
- Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- primary central nervous system lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- primary central nervous system lymphoma treatment landscape brief
- primary central nervous system lymphoma treatment updates RSS
Frequently asked questions about primary central nervous system lymphoma
What drugs treat primary central nervous system lymphoma?
Tracked treatments include Kymriah.
What is the treatment for primary central nervous system lymphoma?
Standard treatment for primary central nervous system lymphoma includes Kymriah. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: primary central nervous system lymphoma patent cliff · primary central nervous system lymphoma CI report
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing